Highlighting the clinical significance of our finding, we identified that two recurrent mutations, IGLL5 and LRP1B, could serve as prognostic biomarkers for pGI-DLBCL patients. This evidence concerns the gene IGLL5 and diffuse large B-cell lymphoma.